Clinical correlation with codon-specific mutations in metastatic colorectal cancer.

Authors

Sophia Kamran

Sophia C. Kamran

Harvard Radiation Oncology Program, Boston, MA

Sophia C. Kamran , Jeffrey W. Clark , Darrell R. Borger , Jackie Szymonifka , Eunice Lee Kwak , Lawrence Scott Blaszkowsky , Janet E. Murphy , Lipika Goyal , Jill N. Allen , Jennifer Yon-Li Wo , Andrew X. Zhu , A. John Iafrate , Ryan Bruce Corcoran , David P. Ryan , Theodore S. Hong

Organizations

Harvard Radiation Oncology Program, Boston, MA, Massachusetts General Hospital Cancer Center, Boston, MA, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, Cancer Research and Biostatistics, Seattle, WA, Massachusetts General Hospital, Harvard Medical School, Boston, MA, Massachusetts General Hospital, Boston, MA, MGH Cancer Center, Brookline, MA, Massachusetts General Hospital and Harvard Medical School, Boston, MA, NSABP/NRG Oncology, and The Massachusetts General Hospital, Boston, MA

Research Funding

Other

Background: Mutational status in colorectal cancer (CRC) impacts response to EGFR inhibition, prognosis, and may affect response to chemoradiation. It is unclear if obesity or other clinical characteristics, including smoking and diabetes, increases the predilection for certain genotypes. The purpose of the following study was to explore the relationship between clinical factors, codon-specific mutations and overall survival (OS). Methods: Metastatic colorectal cancer patients were retrospectively analyzed; clinical characteristics including smoking, diabetes, and body mass index (BMI) were extracted from medical records. Genotyping was performed for > 150 mutations across 15 commonly mutated cancer genes including NRAS, KRAS, PIK3CA, BRAF, and PTEN as part of their clinical management and recorded. Logistic regression was used to establish associations between clinical characteristics and genotypes. Results: 394 metastatic CRC patients were identified. Median age was 58 (range 25-89). 219 (56%) were male. 202 (51%) were non-smokers. 61 had diabetes. 272 patients had a BMI ≥ 25. 136 patients had KRAS mutations, the most common of which was G12D (37%). Diabetes was associated with a higher incidence of KRAS (odds ratio [OR] 1.9 95% CI 1.1-1.3; p = 0.02) and PIK3CA mutations (OR 2.4 95% CI 1.1-5.0; p = 0.02), but not OS. KRAS mutations were not significantly associated with BMI ≥ 25 nor OS. BRAF mutations were significantly associated with poorer OS (hazard ratio [HR] 1.9 95% CI 1.3-2.7; p < 0.001). Current smokers were more likely to have CTNNB1 mutations (OR 11.3 95% CI 1.5-83.2; p = 0.02) and G12D KRAS mutations (OR 5.6 95% CI 1.0-30.3). Current smokers were less likely to have BMI ≥ 25 (OR 0.44; p = 0.02). Patients with BMI ≤ 18.5 have an association with poor OS (HR 2.6 95% CI 1.1-6.4; p = 0.03), although this needs to be corroborated with a larger sample size. Conclusions: A statistically significant association was found between diabetes and KRAS and PIK3CA mutations. The association of BRAF mutations and decreased overall survival was significant, concordant with previous reports. Smokers were more likely to harbor G12D KRAS mutations, and low BMI (≤ 18.5) trended toward poorer overall survival.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Epidemiology/Outcomes

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3596)

DOI

10.1200/JCO.2016.34.15_suppl.3596

Abstract #

3596

Poster Bd #

293

Abstract Disclosures

Similar Abstracts

First Author: Takeshi Yamada

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Circulating tumor DNA–based genomic landscape of KRAS wild-type pancreatic adenocarcinoma.

First Author: Brendon Fusco

Abstract

2023 ASCO Annual Meeting

The clinical and genomic characteristics of KRAS G12D mutated cancers.

First Author: Guomin Lin